Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients
| Autor: | Mohamed A. Adam, Julie Ann Sosa, Daniel P. Nussbaum, Samantha M. Thomas, Dan G. Blazer, Linda M. Youngwirth, Sanziana A. Roman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment General Medicine Perioperative medicine.disease Pancreaticoduodenectomy Radiation therapy 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Pancreatic cancer Internal medicine medicine Adenocarcinoma 030211 gastroenterology & hepatology Surgery Pancreas business Neoadjuvant therapy |
| Zdroj: | Journal of Surgical Oncology. 116:127-132 |
| ISSN: | 0022-4790 1998-2011 |
| DOI: | 10.1002/jso.24630 |
| Popis: | Background Neoadjuvant therapy has theoretical benefits for pancreatic cancer; however, its association with perioperative outcomes remains controversial. This study sought to evaluate variation in use of neoadjuvant therapy and outcomes following pancreatic resection. Methods The National Cancer Data Base (1998-2011) was queried for patients with Stage I or II pancreatic adenocarcinoma who underwent pancreaticoduodenectomy. Subjects were classified by use of neoadjuvant chemotherapy and/or radiation therapy. Factors associated with use of neoadjuvant therapy were evaluated, and outcomes were compared. Results A 18 243 patients were identified; 1375 (7.5%) received neoadjuvant therapy. From 1998 to 2011, use of neoadjuvant therapy increased from 4.3% to 17.0%. Patients receiving neoadjuvant therapy were younger (63.1 vs 66.1 years, P = 0.001) and more likely to receive treatment at an academic facility (64.4% vs 51.4%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text